Ryght AI: Clinical Trial Optimization Agents That Fix Site Feasibility Before Your Study Fails

Overview: How Ryght AI’s AI‑Driven Clinical Trial Optimization Platform Transforms Trial Feasibility, Site Selection, and Enrollment Startup

Ryght AI is an AI‑driven clinical trial optimization platform that uses multi‑agent workflows to improve trial feasibility assessment, site selection, enrollment forecasting, and startup operations. Positioned within the Clinical Trial Optimization Agents, Trial Feasibility & Site Selection Agents, and Enrollment Forecasting & Startup Workflow Agents category, it focuses on one of the most persistent problems in drug development: inefficient, slow, and often inaccurate planning of where and how to run trials. By helping sponsors and CROs predict which sites are likely to perform, anticipate enrollment dynamics, and streamline startup tasks, Ryght AI targets operational friction that directly affects study timelines and cost.

At a high level, Ryght AI ingests historical trial performance data, site characteristics, and other relevant operational and feasibility signals, and applies machine learning and AI agent workflows to continuously analyze and surface the most promising site and country options, expected enrollment trajectories, and potential operational risks. Instead of relying solely on manual feasibility surveys and fragmented spreadsheets, teams can use AI‑generated insights to compare scenarios, stress‑test assumptions, and refine feasibility plans before committing to a strategy. This data‑driven approach supports more objective decision‑making while allowing clinical operations leaders to iterate quickly as new data comes in.

For clinicians, researchers, and operations teams, the impact is felt primarily through faster planning cycles and more predictable execution. By automating parts of feasibility analysis and startup workflows, Ryght AI can reduce administrative burden and coordination overhead, enabling teams to move from study design to site activation in shorter timeframes. More accurate enrollment forecasting and better‑matched site selection also help reduce the risk of under‑enrolling trials or over‑committing sites, which can translate into fewer delays, more efficient use of resources, and improved decision quality across the trial portfolio.

Last checked on 23 May 2026: Ryght AI launched the RyghtSites.com free AI‑powered site search engine and expanded its AI Site Twins‑based platform with new partnerships and Azure Marketplace availability.

What is Ryght AI?

Ryght AI is a clinical trial optimization platform that uses AI Site Twins—dynamic digital replicas of clinical research sites—to support trial feasibility, site selection, enrollment forecasting, and startup workflows for sponsors and contract research organizations. It is designed for life sciences organizations running clinical studies, including pharmaceutical companies, CROs, and other clinical research sponsors that need to identify and prioritize sites globally. The platform is differentiated by its use of digital twin models at global scale, agentic and generative AI to automate feasibility and site ranking, and an enterprise posture that includes SOC 2–type controls and deployment via environments such as Microsoft Azure Marketplace.

Why Do Leading Healthcare Teams Trust Ryght AI?

• Accenture Ventures has made a strategic investment in Ryght AI to support the modernisation of clinical research design and execution for life sciences companies, indicating external due diligence and backing from a large consulting firm.

• Ryght AI has formed partnerships with global CROs and research organizations such as Biorasi and QPS to apply its AI Site Twins and feasibility capabilities in operational clinical trials, demonstrating real‑world adoption in the CRO ecosystem.

• The platform runs on and is distributed via Microsoft Azure Marketplace, aligning it with Azure’s security, privacy, and enterprise governance frameworks, which are widely used by healthcare and life sciences IT teams.

• Ryght AI positions its platform as SOC 2–type compliant when deployed via Azure, addressing expectations for audited controls around security, availability, and confidentiality in clinical research settings.

• The company describes its core approach as using AI Site Twins—digital replicas of clinical research sites built on operational and performance data—to drive feasibility and site selection, offering a technically transparent, data‑based rationale rather than a purely black‑box model.

• Ryght AI has been adopted by academic and cancer research centers such as Emory’s Winship Cancer Institute and the Medical College of Wisconsin in the context of clinical trial feasibility and site selection, indicating validation by independent research institutions.

• Seed and follow‑on venture funding from sector‑focused investors (including Virtue and others) combined with continued platform expansion suggests financial stability and ongoing product development rather than a legacy or stagnating tool.

• The company publicly emphasizes responsible adoption of generative and agentic AI for biopharma, including attention to data security and governance, which aligns with emerging ethical expectations for medical AI platforms.